CMS has admitted that it has no hard evidence to back up deputyadministrator Leslie Norwalk's Congressional testimony thatpharmacies are being paid for Part D scripts on a 15-day billingcycle. Instead, Norwalk's assertion was based on informalinformation provided by Part D drug plans.
They have state-of-the-art distribution centers serving wide geographic areas. They are involved in testing cutting-edge technology. While this may describe the top three national pharmaceutical wholesalers-AmerisourceBergen, Cardinal, and McKesson-which command over 90% of the market, it also covers some regional wholesalers.
Pharmacists in California have finally agreed to technicians checking technicians in hospital settings. Buoyed by studies showing that putting hospital pharmacists on the floor can reduce medication errors and patient deaths, the state board of pharmacy has voted to let techs check medication cassette fills by other technicians.
Mark McClellan, M.D., Ph.D., administrator of CMS, has pledged that the government will be on guard for fraud or practices that mislead seniors covered under prescription drug plans (PDPs). To that end, Medicare has about 500 staff members nationwide to investigate fraud allegations and $80 million available to track and enforce adherence to Medicare policies.
A new set of standardized electronic messages, endorsed after anintense six-week effort, may alleviate some of the problems withthe Part D Medicare benefit, according to pharmacy organizations.
Statistics show that at least one-half of all people with diabeteshave diabetic peripheral neuropathy (DPN). And while many of thesepatients may develop a lack of sensation, approximately 11% havechronic and painful symptoms that seriously affect their quality oflife. For this reason, and the current lack of consensus about thecondition's pathophysiology and most effective treatment, a groupof 11 pain specialists convened in a two-day conference in 2005 tocreate the first diabetic peripheral neuropathic pain (DPNP)guidelines.
For a condition where compliance can be a big issue, a newonce-monthly injection will soon be available to help alcoholicskick the habit. In April, the Food & Drug Administrationapproved Vivitrol (naltrexone for extended-release injectablesuspension), a new treatment option from Alkermes and Cephalon.Vivitrol is indicated for alcohol-dependent patients who are ableto abstain from drinking in an outpatient setting and are notactively drinking at the beginning of treatment.
Let's say several prescription drug plans (PDPs) are asking you toprovide medication therapy management (MTM) services, but each planhas its own requirements. How can you best meet their welter ofneeds?
The pharmacy associations and pharmacy schools in seven ruralstates have signed up for a two-phase demonstration project toshowcase the ability of pharmacists to deliver medication therapymanagement (MTM) services to Medicare patients.
Teva has received permission from the FDA to market rasagiline(Azilect) for the treatment of Parkinson's disease (PD). The newmolecular entity is a monoamine oxidase type B inhibitor that worksby blocking the breakdown of dopamine. Rasagiline was approved asan initial single-drug treatment in early PD and in addition tolevodopa in more advanced patients. Like other MAOIs, rasagilinehas the potential to cause a hypertensive crisis if a patientconsumes tyramine-containing foods while on therapy. The efficacyof the new drug was tested in 404 patients with early disease and1,100 patients with more advanced PD.
Bulk Rx ingredient supplier Spectrum Laboratory has recalled alllots of tacrolimus powder due to sub-potency in some lots. Allpharmacies that have received Spectrum's tacrolimus powder shouldstop using it immediately and contact the company to makearrangements to return it.
The Medicines and Healthcare Products Regulatory Agency, London,has announced that the migraine medication sumatriptan (Imigran) isto be reclassified from Prescription Only Medicine (POM) toPharmacy Medicine (P) status, making it available from pharmacieswithout the need for a prescription. With England setting aprecedent, will the United States be next?
Bausch & Lomb has decided to permanently remove from marketsworldwide its ReNu with MoistureLoc contact lens cleaning solution,based on data suggesting that the product may increasesusceptibility to Fusarium. The company has proposed theformulation as the potential root cause of the increased relativerisk of Fusarium keratitis.
An independent panel convened by the NIH Office of MedicalApplications of Research and the Office of Dietary Supplements hasassessed the available evidence of multivitamin/minerals (MVMs) andmade recommendations regarding certain supplements. The panel'srecommendations include the following: the combined use of calciumand vitamin D protects the bone health of postmenopausal women;antioxidants and zinc help nonsmoking adults with early-stage,age-related macular degeneration; and women of childbearing ageshould take folate daily.
The Consumer Healthcare Products Association has joined forces withthe Partnership for a Drug-Free America to launch an advertisingcampaign designed to curb the abuse of prescription and OTCmedicines and to draw public attention to the substance abuse trendamong teenagers. At dual press conferences held recently inWashington, D.C., and New York, TV, print, and radio public serviceads were unveiled.
CCRx will pay pharmacists as part of a medication review program tobe offered to new Medicare Part D enrollees. The program will helpnew members shift to the benefit and will feature face-to-face drugreviews with a pharmacist.
Medco Health Solutions reached a tentative agreement to pay $163million to settle federal fraud charges stemming from twowhistle-blower suits filed by pharmacists against the giant PBM.Still slated for trial in June, the Medco complaint was filed inDecember 2003 by U.S.
NCPA has charged that last year's FTC conflict-of-interest study ofPBMs and their mail-order pharmacies was flawed and has requestedan immediate correction to the agency's findings. Based on adetailed analysis it commissioned, NCPA concluded that the FTCignored much of what Congress specifically asked it to do orselectively used data and analysis to reach unsubstantiatedconclusions.
CMS will not publicly release current average manufacturer prices(AMP) slated to be used to calculate Medicaid reimbursement ongenerics, according to administrator Mark McClellan. With inputfrom pharmacy, the agency has concluded that the definition of AMPmust be revised to reflect the prices retail pharmacies actuallypay for generics.
Beginning July 1, all Medicare Part D drug plans must use approvedstandardized reject codes developed by groups representingpharmacy, PBMs, and insurers. The change from best practice tomandate was announced by CMS administrator Mark McClellan, who saidit is fundamentally important to reduce administrative burdens onpharmacists.
Sullivan University is seeking to hire the founding dean for a newcollege of pharmacy in Louisville, Ky. The first class of thecollege's Pharm.D. program is scheduled to be admitted in January2008.
Boca Medical Products and the FDA have notified consumers andhealthcare professionals of an extension of an earlier recall ofUltilet insulin syringes and the additional recall of Closercareinsulin syringes because of bacterial contamination withPaenibacillus. This presents a risk of local infection due to softtissue injection with a contaminated syringe as well as a risk ofintroduction of contaminating organisms into a previously sterilevial.
Triax Pharmaceuticals has launched a patient assistance program(PAP) for the prescription acne treatment system Tretin-X(tretinoin). The program is administered through RxHope, a PAP Webportal for uninsured patients.
Results of two studies in patients aged six to 12 years have ledNovartis to update the labeling of dexmethylphenidate HCl (FocalinXR) extended-release capsules. Significant improvements in ADHDsymptoms were observed at every hour up to 12 hours afteradministration of 20 mg of the drug compared with placebo.
AstraZeneca has launched a campaign directed at healthcareproviders after receiving reports of confusion between brand-namedrugs Toprol-XL (metoprolol succinate), Topamax (topiramate,Ortho-McNeil), and Tegretol (carbamazepine, Novartis) and TegretolXR that have led to medication errors. The effort will aim toincrease awareness of the problem and reinforce accurateprescribing and dispensing of Toprol-XL.
Sanofi-Pasteur, manufacturer of the meningococcalpolysaccharide-protein conjugate vaccine (MCV4), has announced ashortage of the vaccine that will last at least through the summerof 2006. Due to the limited supply, CDC is now recommending thatproviders immunize only adolescents at high school entry who havenot previously received MCV4 as well as college freshman living indormitories.
Remember the long list of do's and don'ts CMS came up with latelast year related to how the Medicare Part D plans are to bemarketed? CMS has proposed new guidelines for the 2007 contractyear and has given only one week's time for the public to comment.
Children with active Crohn's disease will now have a new treatmentoption as the FDA has given the regulatory nod to infliximab(Remicade, Centocor) for the treatment of the disease. Themonoclonal antibody works to reduce the inflammation of the bowelassociated with Crohn's by blocking the action of tumor necrosisfactor-alpha and inducing remission of the condition.
Where once treatments were lacking for myelodysplastic syndromes,now several drugs have been approved for this bone marrow disorder